White Paper

COGs Process Economics For Autologous Cell Therapy

Source: Cytiva
Cost GettyImages-918508630

It’s never too early to think about how you can reduce your cost of goods

In the early clinical development stage of autologous cell therapy manufacturing, labor costs often dominate the overall cost of goods (COGs). However, as manufacturing scales up and out, the cost of materials — including media and reagents, consumables, and viral vectors — increases as a percentage of the total COGs.

Review the cost distribution over time for a generic autologous CAR T therapy manufacturing process using the principles of process economics — coupled with insights from scientists and R&D. Plus gain insights into how cell therapy manufacturers can combat these costs.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online